Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Alshimaa Alhanafy

Citation

Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422

Authors

A.M. Alhanafy1, S. El-Hefnawy2, A. Saleh2, O. Elbahr3

Author affiliations

  • 1 Clinical Oncology And Nuclear Medicine, Faculty of Medicine - Menoufia University, 32511 - sheben elkom/EG
  • 2 Medical Biochemistry & Molecular Biology, Faculty of Medicine - Menoufia University, 32511 - sheben elkom/EG
  • 3 3hepatology And Gastroenterology Department, National Liver Institute – Menoufia University, 32511 - sheben elkom/EG

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 161P

Background

Chitinase 3-like 1 (CHI3L1) gene codes for the YKL-40 protein. Serum YKL-40 levels are controlled by polymorphisms in the proximal promoter region of CHI3L1 gene. Aim: We aimed to investigate the association of rs880633 (T/C) polymorphism at CHI3L1 gene with serum YKL-40 production and to evaluate the role of this polymorphism as a risk for HCC and its impact on patient’s survival.

Methods

225 subjects were classified into two groups, group I: included 120 HCC patients and group II: included 105 age & gender matched healthy volunteers. Genotyping of (T/C) polymorphism rs880633 at CHI3L1 gene was analyzed using allelic discrimination assay by Real-Time PCR technique and serum YKL-40 level was determined by ELISA.

Results

There was a significant statistical difference as regards genotype frequency of CHI3L1 gene T/C polymorphism between the two studied groups, with increased frequency of CC genotype among HCC patients and increased frequency of TT genotype among the control group. As regards allelic distribution, C allele was significantly more dominant in HCC patients that have increased HCC risk with odds ratio (CI = 95%) of 2.05(1.40 – 2.99) comparing to T allele. Subjects carrying CC genotype had the highest levels serum YKL40 followed by those with TC genotype, while subjects with TT genotype were found to have the lowest serum YKL40. HCC Patient with TT genotype had significantly longer survival rate than those had TC, CC genotypes, Overall survival of HCC patients revealed that both CC and CT genotypes had significantly shorter survival rate than those had TT genotype (P value <0.05).

Conclusions

CHI3L1 gene variants rs880633 might be a candidate risk factor for HCC. Carriers of CC genotype have highest serum YKL40 levels, are associated with criteria of bad prognosis. So, genotyping of (T/C) polymorphism rs880633 at CHI3L1 gene could predict the patient outcome.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Menoufia University.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.